The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2 ; volume:18 ; number:1 ; day:1 ; month:3 ; year:2018 ; pages:1-14 ; date:12.2018
BMC cancer ; 18, Heft 1 (1.3.2018), 1-14, 12.2018
- Creator
-
Maadi, Hamid
- Contributor
-
Nami, Babak
Tong, Junfeng
Li, Gina
Wang, Zhixiang
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-4143-x
- URN
-
urn:nbn:de:1111-201805039039
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Maadi, Hamid
- Nami, Babak
- Tong, Junfeng
- Li, Gina
- Wang, Zhixiang
- SpringerLink (Online service)
Other Objects (12)
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients